Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 3
2020 3
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bethlehem w. Yacob (1 results)?
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD. Diamond JR, et al. Among authors: yacob bw. Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455. Mol Cancer Ther. 2022. PMID: 34965958 Free PMC article.
BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL. Turner JA, et al. Among authors: yacob bw. Oncogene. 2019 Feb;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7. Epub 2018 Sep 25. Oncogene. 2019. PMID: 30254212
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, Messersmith WA, Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Lang J, et al. Among authors: yacob bw. J Clin Endocrinol Metab. 2020 Jan 1;105(1):26-42. doi: 10.1210/clinem/dgz014. J Clin Endocrinol Metab. 2020. PMID: 31513709 Free PMC article.
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, Eckhardt SG, Messersmith WA, Pitts TM. Hartman SJ, et al. Among authors: yacob bw. Front Oncol. 2021 Mar 25;11:642328. doi: 10.3389/fonc.2021.642328. eCollection 2021. Front Oncol. 2021. PMID: 33869031 Free PMC article.
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR. Capasso A, et al. Among authors: yacob bw. Mol Cancer Ther. 2019 Nov;18(11):1916-1925. doi: 10.1158/1535-7163.MCT-18-1334. Epub 2019 Sep 5. Mol Cancer Ther. 2019. PMID: 31488700 Free PMC article.
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Pitts TM, Pelanda R, Eckhardt SG, Diamond JR. Tentler JJ, et al. Among authors: yacob bw. BMC Cancer. 2020 Nov 4;20(1):1063. doi: 10.1186/s12885-020-07500-1. BMC Cancer. 2020. PMID: 33148223 Free PMC article.
11 results